The FDA said the drug helps manage pain from degenerative diseases and improve the quality of life of cats.
The first drug approved in the United States for the treatment of osteoarthritis in cats. It is also the first approved monoclonal antibody drug approved in the United States. Food and Drug Administration For all animal species.
The drug Sorencia is not a cure for osteoarthritis. The FDA said the drug helps manage pain from degenerative diseases and improve the quality of life of cats.
Osteoarthritis occurs when cartilage is destroyed and the bones of the joints rub against each other. According to the FDA, this can lead to osteophytes, pain, and decreased movement.
The active ingredient is flunebetamab, and the FDA states that it is a monoclonal antibody specific to cats. “It is designed to recognize and attach to proteins called nerve growth factors that are involved in pain regulation.” When that bond occurs, it prevents the pain signal from reaching the cat’s brain.
“Today’s approval is the first treatment option to help cats suffering from this condition and potentially significantly improve their quality of life,” said the director of the FDA’s Veterinary Center. One Stephen M. Solomon said in a statement. We also hope that today’s approval of the first monoclonal antibodies of all animal species by the FDA will expand the research and development of other monoclonal antibody products for the treatment of animal diseases. ”
Approval will follow two masked randomized controlled trials. Cat owners showed baseline scores for cat disability levels before and after treatment. This was evaluated based on specific activities such as jumping on furniture and using the toilet.
Sorencia is provided by injection. It must be prescribed and controlled by a veterinarian. Side effects include vomiting, diarrhea, pain at the injection site, itching of the head and neck, and itching of the skin. The FDA said these tend to be mild.
Cats have arthritis pain management for the first time
Source link Cats have arthritis pain management for the first time